Gene-testing startup's study responds to critics
Navigenics Inc., a gene-testing startup, is responding to criticism that the tests could spur bad healthcare choices by teaming up for a broad study of how the results affect behavior. Navigenics charges customers $2,500 to analyze their DNA to assess their risk of developing more than 20 diseases. Several public health officials have said the science on which the tests by Navigenics and other companies are based is too new to be used for making serious medical decisions. Critics fear that some consumers will use positive results to seek treatments they might not need. Negative results, critics say, could inspire others to be less cautious than they should be about lifestyle choices or preventative care. Navigenics is now joining with the Scripps Translational Science Institute in San Diego in hopes of showing those fears are unfounded.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- 3 Traits Personality Assessments Can't Reveal
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Carondelet to Pay $35M to Settle Fraud Allegations
- CHS Hacked, 4.5M Patient Records Compromised